WellPoint says new hepatitis c drug prices are too high - (Chicago Tribune via NewsPoints Desk)

  • WellPoint commercial business head Ken Goulet asserted that the prices of Gilead Sciences and Johnson & Johnson's new hepatitis C therapies are excessive, as reported the Chicago Tribune.
  • Goulet said that WellPoint is working with regulators and drugmakers to reduce the drugs' prices to a "reasonable" level.

To read more NewsPoints articles, click here.

Reference Articles